Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033332 · ClinicalTrials.gov registry record · Phase 3
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00033332: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00033332 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033332, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide in treating patients who have multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG thalidomide
- DRUG zoledronic acid
- DRUG pamidronate disodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033332
The ClinicalTrials.gov registry entry for NCT00033332 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00033332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033332 about?
NCT00033332 is a clinical study titled "Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexa...
What is the current status of trial NCT00033332?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-04. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00033332?
The interventions under investigation include: dexamethasone (DRUG), thalidomide (DRUG), zoledronic acid (DRUG), pamidronate disodium (DRUG).
Who is sponsoring clinical trial NCT00033332?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.